FTAI Aviation Ltd vs uniQure N.V. Ordinary Shares — how do they compare? FTAI Aviation Ltd trades at $159.09 (market cap $16.75B), while uniQure N.V. Ordinary Shares trades at $21.51 (market cap $1.45B). The key difference: FTAI Aviation Ltd is far larger — about 11.6× uniQure N.V. Ordinary Shares's market cap, and FTAI Aviation Ltd pays a 1.23% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 24 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| FTAI | QURE | |
|---|---|---|
Market Cap | $16.75B | $1.45B |
Volume | 2,940,634 | 3,323,243 |
Sector | Industrials | Health |
52-Week High | $310.04 | $70.59 |
52-Week Low | $152.80 | $9.03 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $19.87B | $707.46M |
Dividend Yield | 1.23% | — |
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $166.87, showing modest daily gains of 0.81% but facing bearish technical signals with 16 sell indicators versus 3 buy signals. The company reported strong revenue growth to $2.51 billion in 2025 with a 19.98% net profit margin, though recent quarters show earnings misses against expectations. Recent developments include a $500 million share repurchase program and acquisition of 27 Boeing 737-700 aircraft, signaling strategic expansion in aerospace services.
Despite technical weakness, FTAI maintains unanimous analyst buy ratings with a $321.25 consensus target representing 92% upside potential. Key risks include consecutive earnings misses and negative operating cash flow, while catalysts include the buyback program and aerospace sector growth. The stock presents a compelling value opportunity if operational execution improves to match analyst optimism.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →